1 Min Read
Oct 19 (Reuters) - Applied Genetic Technologies Corp
* AGTC files investigational new drug application for the treatment of Achromatopsia caused by mutations in the CNGA3 gene Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.